Targeted therapy

• anti-C5 drugs
  2 January 2012

  Types
  eculizumab (INN and USAN, trade name Soliris)
  See also
  targeted therapy

• anti-IL-6 drugs
  2 January 2012

  Wikipedia
  Anti-interleukin-6 agents are a recent class of therapeutics.
  Interleukin-6 is relevant to many inflammatory diseases and many cancers. Hence anti-IL-6 agents have been sought.
  Types
  tocilizumab (Actemra)
  In clinical trials esilimomab for some cancers CNTO-328 ALD-518 CNTO-136 CPSI-2364[6], CDP6038[7]. VX30 ARGX-109 FE301
  FM101

• TNF inhibitors
  2 January 2012

  TNF inhibitors

• RAF inhibitors
  4 March 2010

  Tumours with mutant BRAF are dependent on the RAF-MEK-ERK signalling pathway for their growth.
  ATP-competitive RAF inhibitors inhibit ERK signalling in cells with mutant BRAF, but unexpectedly enhance signalling in cells with wild-type BRAF.
  RAF inhibitors do not inhibit ERK signalling in cells that coexpress BRAF-V600E and mutant RAS. (#20179705#)
  Members
  vemurafenib
  dabrafenib
  LGX818
  TAK-632
  MLN2480
  PLX-4720
  See also
  RAS-ERK pathway inhibitors RAF inhibitors MEK (...)

• targeted therapy
  2 January 2006

  Targets
  receptor tyrosine kinases (RTKs )
  ERBB1 (ErbB: HER1/EGF):
  cetuximab , panitumumab
  erlotinib , gefitinib , lapatinib , vandetanib , neratinib
  ERBB2 (HER2 /neu)
  trastuzumab
  apatinib , neratinib
  C-kit (KIT)
  Axitinib , Sunitinib , Sorafenib
  FLT3 : lestaurtinib
  PDGFR : axitinib , sunitinib , sorafenib
  VEGFR : vandetanib, semaxanib, cediranib, axitinib, sunitinib, sorafenib
  EpCAM : catumaxomab , edrecolomab
  VEGF-A (VEGFA )
  bevacizumab (Avastil)
  fusion (...)

0 | 10 | 20